https://www.wsj.com/articles/panera-bread-set-to-return-to-public-market-11636459201
Summit Therapeutics Presents Ri-CoDIFy Trial Results For Microbiome-Sparing Ridinilazole At IDWeek 2022
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin
Ridinilazole preserved the gut microbiome compared to vancomycin: